Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 16, 2021

SELL
$9.84 - $14.26 $72,816 - $105,524
-7,400 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$10.3 - $21.64 $76,220 - $160,136
7,400 New
7,400 $76,000
Q2 2018

Aug 14, 2018

SELL
$5.3 - $6.9 $21,200 - $27,600
-4,000 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$3.65 - $7.95 $14,600 - $31,800
4,000 New
4,000 $23,000

Others Institutions Holding ADVM

About Adverum Biotechnologies, Inc.


  • Ticker ADVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 99,333,600
  • Market Cap $789M
  • Description
  • Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...
More about ADVM
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.